(L-R) Dr. James F. Young, Chairman, Board of Directors, Novavax; Mr. Stanley C. Erck, President & CEO, Novavax; U.S. Mission Chargé d'Affaires, Patricia Lacina; Mr. Adar Poonawalla, CEO, SII; Mr. Mike Hankey, U.S. Consul General in Mumbai and Dr. Preetha Rajaraman, HHS Health Attaché
Pune, 17 August 2022 - Highlighting 75 years of U.S.-India bilateral relationship and their cooperation on health issues, a delegation from the United States visited the Serum Institute of India (SII) in Pune today and noted the critical role played by U.S.-India cooperation in addressing the COVID-19 pandemic and other global health challenges.
Recognizing India’s partnership and commitment to the world during the pandemic, the event was a celebration of the long-standing relationship in health between the two countries.
The delegation included U.S. Mission Chargé d'Affaires, Patricia Lacina, U.S. Consul General in Mumbai Mike Hankey, Dr. Preetha Rajaraman, HHS Health Attaché, and FDA Country Director Dr. Sarah McMullen. The delegation met with Dr. Cyrus Poonawalla, Chairman & MD, SII, Mr. Adar Poonawalla, CEO, SII, Mr. Stanley C. Erck, President & CEO, Novavax and Dr. James F. Young, Chairman, Board of Directors, Novavax.
The event also highlighted the partnership between Novavax and SII on vaccine manufacturing, which was recognized for its contribution to increasing global access to effective and affordable COVID-19 vaccines. Novavax and SII are key partners in the manufacturing of Novavax’ vaccine, marketed by Novavax as Nuvaxovid™ and by SII as Covovax™.
SII CEO, Adar Poonawalla and U.S. Mission Chargé d'Affaires, Patricia Lacina
In a statement, US Mission Chargé d'Affaires Patricia Lacina said, "The long-standing relationship in health between the United States and India has had a profound impact on the lives of people across both countries and globally. The partnership is vital in addressing the challenges of our times. The public-private economic partnership between both countries plays a key role in ensuring the health and prosperity of our people."
"I am delighted to be in Pune and visit the Serum Institute of India, which has helped save lives around the world during the pandemic," she added.
CEO of Serum Institute of India, Adar Poonawalla said, T"The US and India have been close allies for the longest time. Together, they have created several milestones that have benefitted the citizens and the world, at large."
"The strong cooperation between both the countries on global vaccination and pandemic relief has been inspiring," he said, adding "that in order to keep the growth curve upward and onwards, we will continue to play our role sincerely."
“India has played a crucially important role during the devastating pandemic. As it emerges as one of the fastest growing large economies in the world, it will continue to have a powerful impact on all fronts,” said Stanley C. Erck, President and Chief Executive Officer, Novavax.“The US-India ties are even stronger than before and aligned in values and vision. Novavax and Serum Institute of India are committed to growing these partnerships to leverage our collective dedication, ingenuity, and expertise to protect the health of people everywhere.”
Adar Poonawalla awarded 'Business Leader of the Year' 2023 by the International Advertising Association (IAA) India Chapter
Cyrus Poonawalla Group appoints Keki Mistry as Strategic Advisor to all the Financial Services Ventures led by Adar Poonawalla
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.